The Anti-Fibrotic Drug Development Summit was the first meeting to assemble researchers and program leaders from cross-industry to share experiences and insights on how to better target the fibrotic and inflammatory drivers of these devastating diseases.
Developed in combination with experts from GSK, BMS, Pfizer and many more, this forum focused on how the underlying fibrotic biology can be more effectively drugged, to discern which models of fibrosis are the most robust and how biomarkers can be implemented into improved clinical trials designs.
Thank you to all who joined us at this critical industry event and helped shape the future treatment of fibroproliferative diseases. Register your interest for the 2018 meeting for all the latest updates.
“As a newcomer to the NASH space, I found the meeting to be incredibly informative and intellectually stimulating. Well organized and very comprehensive”.
NASH Summit Boston Attendee, Inception Sciences